EXEL
EXEL
NASDAQ · Biotechnology

Exelixis Inc

Large-Cap Stocks Blue Chip Stocks Biotech Stocks Healthcare Stocks
$72.09
+2.52 (+3.62%)
As of Nov 9, 6:55 PM ET ·
EXEL News1 articles
Exelixis FDA Review Extension Pushes Zanzalintinib Decision to 2027
FDA extends Exelixis' zanzalintinib-atezolizumab review to March 2027 after updated data; EXEL shares drop 5%.
Analysis